A meta-analysis of 19 double-blind RCTs involving over 120,000 participants found no evidence for 62 out of 66 adverse effects currently listed on statin labels.
Beyond muscle symptoms and diabetes, only four outcomes—abnormal liver tests, urinary composition changes, and edema—showed a statistically significant increase.
Commonly reported issues such as cognitive impairment, depression, and sleep disturbances were not supported by the blinded data.
The findings suggest that current product labels may unnecessarily contribute to the nocebo effect and treatment non-adherence.
Background: The Disconnect Between Labels and Evidence
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
